Skip to main content

Table 5 Multivariate analysis for disease free survival

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

 

HR

95% CI

P-value

tumor size (≥ 5 cm)

1.260

(0.602, 2.637)

0.539

number of lymph nodes (≥ 10)

7.366

(2.982, 18.197)

< 0.001

ER (-)

0.988

(0.316, 3.089)

0.984

PR (-)

0.717

(0.254, 2.025)

0.530

bcl-2 (-)

2.895

(1.090, 7.690)

0.033

p53 (> 25%)

1.065

(0.507, 2.237)

0.868

c-erbB2 (3+)

3.535

(1.616, 7.731)

0.002

Ki-67 (≥ 5%)

1.247

(0.614, 2.534)

0.541